NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis

Madrigal Pharmaceuticals, Inc. (MDGL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

MDGL

$541.08

−$1.53 (−0.28%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MDGL with… →

MDGL Key Statistics

As of Sep 4, 2026
Trading
Open
$536.82
Previous Close
$542.61
Day's Range
535.60–547.92
52-Week Range
393.61–615.00
Volume
177.20K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.99
Valuation
Market Cap
$12.50B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
56.22
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.74
EPS (ttm)Profit attributable to each share over the last twelve months.
−14.00
Financials (FY)
Revenue (FY)
$958.40M+432.05%
Net Income (FY)
−$288.28M
Profit marginThe share of revenue left as profit after all costs and taxes.
−25.32%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
23.10M
1-Year Return
+25.48%
Dividend and dates
Earnings Date
November 4, 2026
Avg Volume
352.42K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MDGL Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−7.09%
2025+88.72%
2024+33.36%
2023−20.28%
2022+242.52%
2021−23.77%
2020+22.02%
2019−19.17%
2018+22.80%
2017+516.04%
2016 (partial year)+92.26%

As of September 4, 2026.

MDGL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$958.40M−$288.28M−30.1%
2024$180.13M−$465.89M−258.6%
2023$0.00−$373.63M—
2022$0.00−$295.35M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$958.40M$902.26M−$300.10M−$288.28M−30.1%
2024$180.13M$173.90M−$497.88M−$465.89M−258.6%
2023$0.00$0.00−$380.50M−$373.63M—
2022$0.00$0.00−$293.57M−$295.35M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MDGL Valuation vs Biotechnology Median

Median of 656 stocks
MetricMDGLBiotechnology medianvs median
P/S ratio9.7415.2636% below
Profit margin−25.32%0.00%25.3 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 17 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Madrigal Pharmaceuticals, Inc. (MDGL) is capitalised at $12.50B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 915 employees.

The most recent close on file for MDGL is $541.08, dated September 4, 2026. That is −$1.53 (−0.28%) against the previous close. The 52-week range on file runs from $393.61 to $615.00. The latest close sits 37.47% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $958.40M. That is +432.05% against the prior fiscal year, when revenue was $180.13M. The same year closed with a net loss of $288.28M. The reported profit margin is −25.32%. That is 25.3 percentage points below the Biotechnology median of 0%. Trailing earnings per share are −14.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $958.40M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 56.22. Measured against sales, the shares trade at 9.74 times revenue. On price-to-sales that is 36.21% below the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Beta against the wider market is reported at −0.99. Daily returns over the trailing 10 years annualize to a volatility of 116.5%. The trailing one-year price return is +25.48%. Across 10 years the annualized return works out at +46.51%.

Growth & Income

No dividend is on file for MDGL.

Across the complete calendar years on file, 2017 returned +516.04% and 2021 returned −23.77%. Of the 9 complete calendar years on file, 6 finished higher. So far in 2026 the price is −7.09%.

Peer Comparison

Madrigal Pharmaceuticals, Inc. (MDGL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Madrigal Pharmaceuticals, Inc. MDGL $12.50B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Madrigal Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.

Visit website →